$heff's $tation of $tocks & $olid DD

[closenow]

AFFY 6.36 - UPCOMING CATALYST


April 26-30: Affymax and Takeda to Present Additional Peginesatide Phase 3 Data in Dialysis Patients at the National Kidney Foundation (NKF).
2Q: submit NDA, FDA advisory committee review, and initiating a Phase 3b to evaluate the process and outcomes of converting dialysis centers from a three times a week ESA to a once monthly ESA.

This same pattern happened to SPPI. Most investors try to chase the pps up.

The smart and patient ones buy when nobody wants to touch and wait for the big pay day especially when fundamentals are very sound.

This is a company with ZERO long term debt. This is rare find in the biotech space.

Target near term PPS is around $14. Check out it for yourself.

http://stockcharts.com/def/servlet/SC.pn...

From CEO March 30th letter in Annual Report (pg 4):
"The top priority for us in 2011 is to submit the NDA for peginesatide to the FDA in the second quarter of the
year. If all goes as planned, the FDA will accept our application for filing approximately two months after
submission, and begin their intensive review process.
This could position us for potential product approval and launch some time in 2012."


Do your own DD. here are some helpful links.

1. new data will be released on 4/27 at conf. Nobody will go to a conference willingly to announce bad data. It just does not make sense
http://www.investors.affymax.com/release...
2. All analysts have a buy rating with over $10 as the target.
http://www.dailyfinance.com/earnings/aff...
3. A group of investors just bought $50M shares at a $5.9. They know the potential. History shows that major investors usually end up making money on such deals.
http://www.investors.affymax.com/release...
4. The down days have light vloume once again indicating that most long term investors are hoarding their shares.